Executive Actions Tracker

This executive order directs a federal campaign to suppress tick and invasive mosquito populations, targeting a 90 percent reduction in invasive mosquitoes and a 50 percent reduction in ticks across the District of Columbia by 2028. It directs the Secretaries of the Interior, Agriculture, and Health and Human Services, the EPA Administrator, and the GSA Administrator to develop the campaign within 60 days, requires the EPA Administrator to submit a regulatory framework for releasing tick and mosquito control technologies within 60 days, and directs prize competitions and research programs for diagnostics, prophylactics, therapeutics, and non-chemical control methods within 90 days. It also directs exploration of allergy-style labeling for products containing significant alpha-galactose within 60 days.

Clients in Life Sciences · Environmental

This EO directs the Secretary of War and the Secretary of Veterans Affairs to establish, within 180 days, updated information technology systems and guidance for ongoing sharing of Official Military Personnel Files and Service Treatment Records, deploy AI-based digital tools consolidating veterans' benefits access, and, within 30 days, ensure records transfer to the Department of Veterans Affairs immediately upon a service member's discharge. It also requires, within 120 days and in consultation with HHS and OMB, review and modification of existing IT contracts to add interoperability requirements, and directs the Secretary of War, within 180 days, to update the Transition Assistance Program to connect separating service members to jobs, training, or apprenticeships and to veterans' benefits representatives.

Clients in Healthcare · AI, Robotics and Quantum · Aerospace, Defense & Government Services

This executive order establishes "Gold Standard Childhood Vaccine Recommendations" organizing childhood immunizations into three categories (recommended for all children, recommended for high-risk groups, and based on shared clinical decision-making) and directs all agencies to advance them. It directs the Secretary of HHS, through the HHS Task Force on Safer Childhood Vaccines, to present plans to the President within 90 days on offering single-disease vaccines starting with MMR, adjusting the federal vaccine schedule, developing alternative adjuvants, and improving safety monitoring. It also directs the Attorney General to further legal actions challenging state laws that conflict with obligations related to parental authority, religious freedom, disability accommodations, and equal protection, and directs the Departments of Justice, Education, and HHS to ensure their contractors and grantees, including states and localities, provide religious and medical exemptions from immunization requirements where required by federal law.

Clients in Life Sciences · Healthcare

This EO directs the Administrator of the EPA to prioritize registration actions for substances that serve as alternatives to older active ingredients and to review data for registered pre-harvest desiccation uses, including accurate chemical labeling. It directs the Secretary of Agriculture, the Secretary of HHS, and the Administrator to expedite a research and evaluation framework for cumulative chemical exposure in the food supply, and directs the Secretary of HHS to issue a grand prize challenge through the National Institutes of Health on cumulative chemical exposures and to prioritize research through the Advanced Research Projects Agency for Health on technologies reducing reliance on conventional chemical crop protection. It also directs the Secretary of Agriculture to maximize funding of the Regenerative Pilot Program and evaluate expanding it through public-private partnerships.

Clients in Food and Beverage · Environmental · Life Sciences

This EO directs the Centers for Disease Control and Prevention and its Advisory Committee on Immunization Practices to review an HHS scientific assessment comparing U.S. childhood vaccine recommendations with those of peer nations and to take appropriate steps to update the U.S. childhood and adolescent vaccine schedule, with consideration of flexibility for parents and doctors in timing and sequencing. It further directs all executive departments and agencies to align actions, regulations, funding, and coverage with the ACIP-recommended, CDC-adopted schedule, including continued coverage of scheduled immunizations without cost sharing by private insurance and coverage under Medicaid, the Children's Health Insurance Program, and the Vaccines for Children Program. It also directs the HHS Director of the Office of Intergovernmental and External Affairs to inform state officials of the order's policies and make the scientific assessment available to inform state vaccination laws.

Clients in Healthcare · Life Sciences · Insurance

This executive order directs the Commissioner of Food and Drugs to grant Commissioner's National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy designation and directs the FDA and Drug Enforcement Administration to establish a pathway for patient access to psychedelic drugs, including ibogaine compounds, under the Right to Try Act. It directs the Secretary of Health and Human Services to allocate at least $50 million through the Advanced Research Projects Agency for Health to partner with state programs advancing psychedelic drugs for serious mental illness, directs HHS, FDA, and the Department of Veterans Affairs to collaborate on clinical trials and sign data-sharing memoranda, and directs the Attorney General, in consultation with HHS, to review Schedule I products that complete Phase 3 trials for potential rescheduling.

Clients in Life Sciences · Healthcare

This proclamation, issued under section 232 of the Trade Expansion Act, imposes a 100 percent ad valorem tariff on imports of patented pharmaceuticals and associated pharmaceutical ingredients, with a 20 percent rate for companies with onshoring plans approved by the Secretary of Commerce (rising to 100 percent on April 2, 2030), a 15 percent rate for products of Japan, the European Union, the Republic of Korea, and Switzerland and Liechtenstein jointly, a 10 percent rate for the United Kingdom, and a zero rate for orphan drugs, certain specialty products, and companies with Most-Favored-Nation pricing agreements (until January 20, 2029). Generic pharmaceuticals are excluded at this time. Tariffs take effect July 31, 2026 for companies listed in Annex III and September 29, 2026 for others. The Secretary of Commerce and the Secretary of Health and Human Services are directed to pursue negotiations of agreements addressing the national security threat and update the President within 90 days.

Clients in Life Sciences · Healthcare

This executive order establishes the White House Great American Recovery Initiative, co-chaired by the Secretary of Health and Human Services and the Senior Advisor for Addiction Recovery, with an Executive Director reporting to the Assistant to the President for Domestic Policy. The Initiative, composed of the Attorney General and numerous other agency heads, is directed to coordinate the federal response to the addiction crisis, increase awareness of addiction, advise agency heads on integrating prevention, treatment, and recovery programs and directing grants to support addiction recovery, and consult with states, tribal nations, local jurisdictions, and community, faith-based, private-sector, and philanthropic entities on treatment strategies.

Clients in Healthcare

This EO directs the expedited rescheduling of marijuana from Schedule I to Schedule III, acknowledging its accepted medical use and reduced abuse potential. It further calls for a regulatory framework and improved research on both medical marijuana and hemp-derived CBD products, including clear guidance on THC limits and accurate product labeling. The order aims to close gaps in medical knowledge so patients and providers may access safe, effective, and well-informed treatment options.

Clients in Cannabis · Healthcare · Life Sciences

This memorandum directs federal health officials to review childhood vaccine recommendations from peer, developed countries and update U.S. guidelines if superior, evidence-based practices are identified, while maintaining access to all currently available vaccines.

Clients in Healthcare · Life Sciences

This EO directs federal agencies to harness artificial intelligence to accelerate pediatric cancer research, improve data sharing, and enhance clinical care, prioritizing innovation, investment, and interoperability in health data. It establishes a coordinated effort to use AI-enabled solutions for better diagnostics, treatments, and prevention, while ensuring patient privacy and encouraging public and private sector engagement.

Clients in Healthcare · Life Sciences · AI, Robotics and Quantum

This proclaims August 31 through September 6, 2025, as Overdose Prevention Week.

Clients in Healthcare

This EO directs HHS to identify approximately 26 critical drugs and ensure a six-month supply of their active pharmaceutical ingredients —preferably sourced domestically—is stockpiled in the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Additionally, it requires an updated plan to maintain reserves for essential medicines, including opening a second SAPIR repository, to bolster supply chain resilience against future public health emergencies.

Clients in Life Sciences · Healthcare

This proclamation exempts certain commercial sterilization facilities identified in Annex I from compliance with the EPA's April 5, 2024 final rule on ethylene oxide emissions standards (89 FR 24090), extending each compliance deadline under that rule by 2 years, pursuant to section 112(i)(4) of the Clean Air Act. During each 2-year extension, the listed facilities remain subject to the emissions and compliance obligations in effect before the rule's issuance. The President determines that the technology required to implement the rule is not commercially available and that the exemption is in the national security interests of the United States.

Clients in Life Sciences · Healthcare · Environmental

This Executive Order directs federal agencies to adopt rigorous “Gold Standard Science” practices to restore public trust in the integrity of federally funded scientific research. Citing past misuse of scientific data, reproducibility concerns, and politicization of science, the order requires that scientific information used in policy decisions be transparent, reproducible, and objectively evaluated. Within 30 days, the Office of Science and Technology Policy (OSTP) must issue guidance outlining these standards, after which agencies must update their scientific integrity policies and report implementation actions within 60 days. Agencies are required to disclose influential data and models (with limited exceptions), communicate uncertainty and assumptions clearly, and apply a “weight of scientific evidence” approach in decision-making. Interim policies revert to those in place as of January 19, 2021, and actions taken between January 20, 2021, and January 20, 2025, must be reviewed for compliance. Each agency must also establish internal processes to address violations. The order applies to all employees and contractors involved in scientific activities, with limited waivers permitted by OMB and OSTP.

Clients in Life Sciences · Healthcare · Environmental · ESG and Sustainability

This Executive Order seeks to align U.S. prescription drug prices with those in comparably developed countries by implementing a “most-favored-nation” pricing strategy. It directs the Secretary of Health and Human Services to communicate price targets to pharmaceutical manufacturers within 30 days and to facilitate direct-to-consumer programs offering drugs at the most-favored-nation price. If significant progress is not made, the order authorizes additional actions, including proposed rulemaking, importation certifications, antitrust enforcement, export controls, and potential FDA regulatory reviews. The order also calls on the Department of Commerce and USTR to address international pricing practices that contribute to disproportionately high drug costs for American consumers.

Clients in Life Sciences · Healthcare

This Executive Order aims to strengthen the U.S. pharmaceutical supply chain by removing regulatory barriers to domestic manufacturing. It directs the FDA, EPA, and U.S. Army Corps of Engineers to review and streamline applicable regulations and guidance within 180 days to improve the timeliness and predictability of agency review processes. The order also calls for enhanced inspections of foreign pharmaceutical facilities, increased transparency on inspection activities, and centralized coordination of environmental permits for new manufacturing sites. The policy goal is to create a more resilient, competitive, and secure domestic pharmaceutical manufacturing base.

Clients in Life Sciences · Healthcare · Environmental

This EO seeks to optimize Federal health care programs, intellectual property protections, and safety regulations to provide access to prescription drugs at lower costs. The EO directs various agency actions to achieve this goal.

Clients in Healthcare · Life Sciences

This EO states that the Federal Government will promote universal access to clear and accurate healthcare prices. The Secretaries of the Treasury, Labor, and HHS are directed to take all necessary and appropriate action to rapidly implement and enforce the healthcare price transparency regulations issued pursuant to Executive Order 13877 (June 24, 2019, Improving Price and Quality Transparency in American Healthcare to Put Patients First) to require the disclosure of the actual prices of items and services, not estimates, issue updated guidance or proposed regulatory action ensuring pricing information is standardized and easily comparable across hospitals and health plans, and issue guidance or proposed regulatory action updating enforcement policies designed to ensure compliance with the transparent reporting of complete, accurate, and meaningful data within 90 days.

Clients in Healthcare · Insurance

This EO directs the Assistant to the President for Domestic Policy to submit a list of policy recommendations on protecting IVF access and reducing out-of-pocket and health plan costs for IVF treatment to the President within 90 days.

Clients in Healthcare · Life Sciences · Insurance

This EO directs all executive departments and agencies that address health or healthcare to focus on reversing chronic disease, including the following actions: all federally funded health research should use transparency and open-source data and eliminate conflicts of interest; NIH and other federal health research initiatives should prioritize research on chronic illness; agencies should work with farmers to ensure US food is healthy, abundant, and affordable; and agencies should ensure availability of expanded treatment options and flexible insurance coverage for lifestyle changes/disease prevention. Further, the Make America Healthy Again Commission is established with the initial mission to advise the President how to address childhood chronic disease (reports due in 100 days and 180 days).

Clients in Healthcare · Life Sciences · Food and Beverage

This EO states that it is the policy of this administration, consistent with the Hyde Amendment, to end Federal taxpayer funds for elective abortion. Further, it revokes EO 14076 (Protecting Access to Reproductive Healthcare Services) and EO 14079 (Securing Access to Reproductive and Other Healthcare Services). The Director of OMB shall promulgate guidance to the heads of executive departments and agencies related to implementation.

Clients in Healthcare

This memo revokes the 1/28/21 PM and reinstates the 1/23/17 PM, also called The Mexico Policy. Further, the Secretary of State is directed to implement a plan to extend the requirements for the reinstated PM to global health assistance furnished by all departments or agencies. The Secretary of State shall also take actions to ensure that US taxpayer dollars do not fund organizations or programs that participate in coercive abortion or involuntary sterilization.

Clients in Healthcare

This memorandum revokes the Presidential Memorandum of January 28, 2021 (Protecting Women's Health at Home and Abroad) and reinstates the Presidential Memorandum of January 23, 2017 (The Mexico City Policy). It directs the Secretary of State, in coordination with the Secretary of Health and Human Services, to implement a plan extending the reinstated memorandum's requirements to global health assistance furnished by all departments or agencies. It further directs the Secretary of State to ensure U.S. taxpayer dollars do not fund organizations or programs that support or participate in the management of a program of coercive abortion or involuntary sterilization.

Clients in Healthcare

Announces the intent to withdraw from the WHO. Revokes Executive Order 13987 (Organizing and Mobilizing the United States Government to Provide a Unified and Effective Response to Combat COVID–19 and to Provide United States Leadership on Global Health and Security). Pauses transfer of any government funds to the WHO and recalls/reassigns government personnel and contractors working in any capacity with the WHO. Requires review and replacement of the 2024 US Global Health Security Strategy as soon as practicable.

Clients in Healthcare · Life Sciences